Drug Profile
LP 0155
Alternative Names: LEO-134310; LP0155; SEGRA - LEO PharmaLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Antipsoriatics; Nonsteroidal anti-inflammatories; Skin disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Plaque psoriasis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (Topical, Liquid)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in Denmark (Topical)
- 01 Feb 2019 LEO Pharma completes a phase I trial in Plaque psoriasis in Germany (NCT03669757)